要说年底最热闹最惊喜的大厂事儿，莫过于上着班，突然收到了来自老板的投喂。 事情的发展出乎意料，却又在意料之中——最先被抓住的果然还是打工人的胃。 一年卖出10万只的爆款烤鸡立马让我走不动道了。焦黄酥脆的烤鸡香气四溢，浇上精心调制的料汁后，入口酸甜，配以西兰花、圣女果、玉米等，美味又 解腻。据说，这只爆款烤鸡的背后，是一位真正的"厨神"——王师傅入行20多年，曾任北京一家知名连锁西餐厅区域厨师长，在京城西餐圈享有声誉。 就在前几天，10万份巧克力抵达京东多地职场。于是，打工人上班暂停，穿过连通各栋办公楼的室内连廊，提前走进了新年的氛围里。 图源：@momo、@东南早报 为了也感受下提前过年的氛围，氢商业编辑特意去了趟亦庄，瞅瞅这波热闹背后，大厂们到底还有什么惊喜。 01 光餐厅就建了22层， 大厂的配套基础设施能有多离谱？ 烤鸡 民以食为天。京东北京园区的职场餐厅有22层、5万平方米，200多个档口，每天提供2500多款菜品，需求细到有甲状腺友好窗口，提供的都是无碘盐食 物。 除了食堂档口，园区还引入了好几十家餐饮商户，基本都是八折、八五折，听说京东人甚至直接把楼里的喜茶喝成了"全北京销量第一"的门店。 如果不 ...

Core Insights - CVS Health reported strong Q3 2025 earnings, with adjusted EPS of $1.60, a 46.8% increase year over year, surpassing estimates by 17.65% [2] - Total revenues for Q3 reached $102.87 billion, reflecting a 7.8% year-over-year growth and exceeding consensus estimates by 4.66% [3] Revenue Breakdown - Health Services revenues increased by 11.6% year over year to $49.27 billion, driven by pharmacy drug mix and brand inflation, despite a 1.8% decline in total pharmacy claims processed [4] - Pharmacy & Consumer Wellness segment revenues rose 11.7% year over year to $36.21 billion, primarily due to increased prescription volume [5] - Health Care Benefits segment revenues reached $36 billion, up 9.1% year over year, influenced by growth in the Government business related to the Inflation Reduction Act [5] Margin Performance - Total cost of sold products increased by 7.7% to $57.05 billion, while gross profit rose by 7.9% to $45.83 billion, leading to a gross margin of 44.6% [6] - Adjusted operating margin expanded by 12 basis points to 33.6%, despite a 6.9% rise in total operating expenses [6] Liquidity Position - CVS Health ended Q3 2025 with cash and cash equivalents of $9.10 billion, down from $11.79 billion in the previous quarter, while long-term debt increased to $60.51 billion [7] - Cumulative net cash from operating activities remained stable at $7.25 billion compared to the previous year [7] 2025 Guidance - The company raised its 2025 adjusted EPS guidance to a range of $6.55-$6.65, up from the previous range of $6.30-$6.40, with the current consensus estimate at $6.36 [8] Market Performance - CVS Health's stock has shown a positive trend, gaining approximately 4.1% since the last earnings report, outperforming the S&P 500 [1] - The stock currently holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return in the coming months [11]